In this issue:
Retention of TNF inhibitors in older patients with ankylosing spondylitis
Gender differences in treatment response to ixekizumab in patients with axSpA
Breakthrough SARS-CoV-2 infections in vaccinated patients taking immunosuppressants
VE against SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases
Efficacy and safety of deucravacitinib in psoriatic arthritis
Persistence and effectiveness of ustekinumab or TNF inhibitors in psoriatic arthritis
Factors predicting axSpA among first-degree relatives of patients with ankylosing spondylitis
Central obesity in patients with axSpA
MRI characteristics in patients with spondyloarthritis and heel enthesitis
Psoriasis and imaging progression in early axSpA
Effects of filgotinib on spine inflammation in ankylosing spondylitis
Tapering of TNF inhibitors in patients with axSpA
Whole spine MRI predicts radiographic progression and inflammatory activity in axSpA
Treatment responses in psoriatic arthritis axial disease according to HLA-B27 status
Please login below to download this issue (PDF)